High density lipoprotein future or investigational therapies
|
High Density Lipoprotein Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Clinical Trials |
|
Case Studies |
|
High density lipoprotein future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of High density lipoprotein future or investigational therapies |
|
FDA on High density lipoprotein future or investigational therapies |
|
CDC on High density lipoprotein future or investigational therapies |
|
High density lipoprotein future or investigational therapies in the news |
|
Blogs on High density lipoprotein future or investigational therapies |
|
Risk calculators and risk factors for High density lipoprotein future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aarti Narayan, M.B.B.S [2]; Raviteja Guddeti, M.B.B.S. [3]
Overview
There are promising future therapies that include CETP inhibitors, which are currently in the experimental phase. A combination therapy with statins and ACE inhibitors is also a safe option in patients with HDL levels who also share features with dysmetabolic syndrome. However, the preventive effects of these two drugs tend to be cumulative.[1]
The Need
The importance of increasing serum levels and functionality of HDL-C in lowering residual cardiovascular risks in patients with acute coronary syndromes cannot be over-emphasized. Recent studies proving the failures of orally active medications that increase serum levels of HDL-C to potentially improve cardiovascular outcomes, such as niacin in the AIM-HIGH Trial, have shifted the focus of researchers to other targets of HDL therapies aimed at increasing the serum levels of HDL as well as its functionality i.e., cellular cholesterol efflux and HDL-mediated reverse cholesterol transport mechanisms.
HDL Infusion/Mimetics
Clinical Significance
Medications
ApoA-1 Milano
CSL-112
CER-001
APP018
Potential Therapeutic Considerations
Cholesterol Ester Transfer Protein (CETP) Inhibition
Torcetrapib
Dalcetrapib
Anacetrapib
Evacetrapib
Other Therapies
De-lipidated HDL
Endocannabinoid Receptor Blockers
JTT-705
CETi-1 Vaccine
RVX-208
References
- ↑ Liem AH, Jukema JW, van Veldhuisen DJ (2003). "Secondary prevention in coronary heart disease patients with low HDL: which options do we have?". International Journal of Cardiology. 90 (1): 15–21. PMID 12821213. Unknown parameter
|month=ignored (help)